|
|
Volumn 31, Issue 1, 2002, Pages 105-106
|
|
Commentary: Biostatistics, biological mechanisms and Bayes: Lessons from the magnesium trials
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CAPTOPRIL;
FIBRINOLYTIC AGENT;
MAGNESIUM;
NITRATE;
MAGNESIUM;
METHODOLOGY;
ACCURACY;
ACUTE HEART INFARCTION;
BAYES THEOREM;
BIOSTATISTICS;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
HEART INFARCTION SIZE;
HEART LEFT VENTRICLE FAILURE;
HEART PROTECTION;
HUMAN;
HYPOTHESIS;
INFORMATION PROCESSING;
ISCHEMIC HEART DISEASE;
MEDICAL RESEARCH;
META ANALYSIS;
METHODOLOGY;
MORTALITY;
NOTE;
POPULATION SIZE;
PRIORITY JOURNAL;
PROBABILITY;
RANDOMIZED CONTROLLED TRIAL;
REPERFUSION INJURY;
RISK ASSESSMENT;
TREATMENT OUTCOME;
|
|
EID: 0036210838
PISSN: 03005771
EISSN: None
Source Type: Journal
DOI: 10.1093/ije/31.1.105 Document Type: Note |
|
Times cited : (1)
|
|
References (10)
|
